High expression of osteoglycin decreases gelatinase activity of murine hepatocarcinoma Hca-F cells

World Journal of Gastroenterology

Volumn 15, Issue 48, 2009, Pages 6117-6122

  Cui, Xiao Nan ^a   Tang, Jian Wu ^a   Song, Bo ^a   Wang, Bo ^a   Chen, Shan Yan ^b   Hou, Li ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gelatinases; Genes; Hepatocellular carcinoma; Neoplasm metastasis; Osteoglycin; Transfection

Indexed keywords

GELATINASE; MESSENGER RNA; OSTEOGLYCIN; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL CULTURE; DISEASE MODEL; ENZYME ACTIVITY; GENETIC TRANSFECTION; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ZYMOGRAPHY;

EID: 75349094401     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.6117     Document Type: Article

References (32)

1. Das S, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci 2008; 1131: 235-241
2. Chu H, Zhou H, Liu Y, Liu X, Hu Y, Zhang J. Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability. Int J Biochem Cell Biol 2007; 39: 197-205
3. Zhou H, Jia L, Wang S, Wang H, Chu H, Hu Y, Cao J, Zhang J. Divergent expression and roles for caveolin-1 in mouse hepatocarcinoma cell lines with varying invasive ability. Biochem Biophys Res Commun 2006; 345: 486-494
4. Williamson RE, Darrow KN, Giersch AB, Resendes BL, Huang M, Conrad GW, Chen ZY, Liberman MC, Morton CC, Tasheva ES. Expression studies of osteoglycin/ mimecan (OGN) in the cochlea and auditory phenotype of Ogn-deficient mice. Hear Res 2008; 237: 57-65
5. Cui X, Song B, Hou L, Wei Z, Tang J. High expression of osteoglycin decreases the metastatic capability of mouse hepatocarcinoma Hca-F cells to lymph nodes. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 349-355
6. Ries C, Kolb H, Petrides PE. Regulation of 92-kD gelatinase release in HL-60 leukemia cells: tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol ester-induced secretion. Blood 1994; 83: 3638-3646
7. Cohen M, Meisser A, Bischof P. Metalloproteinases and human placental invasiveness. Placenta 2006; 27: 783-793
8. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34
9. Fridman R, Sweeney TM, Zain M, Martin GR, Kleinman HK. Malignant transformation of NIH-3T3 cells after subcutaneous co-injection with a reconstituted basement membrane (matrigel). Int J Cancer 1992; 51: 740-744
10. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009; 26: 19-34
11. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-630
12. Ameye L, Young MF. Mice deficient in small leucinerich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002; 12: 107R-116R
13. Tasheva ES, Koester A, Paulsen AQ, Garrett AS, Boyle DL, Davidson HJ, Song M, Fox N, Conrad GW. Mimecan/ osteoglycin-deficient mice have collagen fibril abnormalities. Mol Vis 2002; 8: 407-415
14. Plaas AH, West LA, Thonar EJ, Karcioglu ZA, Smith CJ, Klintworth GK, Hascall VC. Altered fine structures of corneal and skeletal keratan sulfate and chondroitin/dermatan sulfate in macular corneal dystrophy. J Biol Chem 2001; 276: 39788-39796
15. Tasheva ES, Maki CG, Conrad AH, Conrad GW. Transcriptional activation of bovine mimecan by p53 through an intronic DNA-binding site. Biochim Biophys Acta 2001; 1517: 333-338
16. Shanahan CM, Cary NR, Osbourn JK, Weissberg PL. Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 2437-2447
17. Tasheva ES, Funderburgh ML, McReynolds J, Funderburgh JL, Conrad GW. The bovine mimecan gene. Molecular cloning and characterization of two major RNA transcripts generated by alternative use of two splice acceptor sites in the third exon. J Biol Chem 1999; 274: 18693-18701
18. Tasheva ES. Analysis of the promoter region of human mimecan gene. Biochim Biophys Acta 2002; 1575: 123-129
19. Tasheva ES, Conrad GW. Interferon-gamma regulation of the human mimecan promoter. Mol Vis 2003; 9: 277-287
20. Ge G, Seo NS, Liang X, Hopkins DR, Hook M, Greenspan DS. Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem 2004; 279: 41626-41633
21. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13: 7003-7011
22. Lyons AJ, Jones J. Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int J Oral Maxillofac Surg 2007; 36: 671-679
23. Alakus H, Grass G, Hennecken JK, Bollschweiler E, Schulte C, Drebber U, Baldus SE, Metzger R, Holscher AH, Monig SP. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 2008; 23: 917-923
24. Herszenyi L, Sipos F, Galamb O, Solymosi N, Hritz I, Miheller P, Berczi L, Molnar B, Tulassay Z. Matrix metalloproteinase-9 expression in the normal mucosa-adenomadysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res 2008; 14: 31-37
25. Zhao T, Xia WH, Zheng MQ, Lu CQ, Han X, Sun YJ. Surgical excision promotes tumor growth and metastasis by promoting expression of MMP-9 and VEGF in a breast cancer model. Exp Oncol 2008; 30: 60-64
26. Matsunaga Y, Koda M, Murawaki Y. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. Res Commun Mol Pathol Pharmacol 2004; 115-116: 143-150
27. Tu G, Xu W, Huang H, Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 2008; 15: 1388-1395
28. Macri L, Silverstein D, Clark RA. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 2007; 59: 1366-1381
29. Tufvesson E, Westergren-Thorsson G. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett 2002; 530: 124-128
30. Zafiropoulos A, Tzanakakis GN. Decorin-mediated effects in cancer cell biology. Connect Tissue Res 2008; 49: 244-248
31. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 2001; 189: 266-274
32. Cho HJ, Lee TS, Park JB, Park KK, Choe JY, Sin DI, Park YY, Moon YS, Lee KG, Yeo JH, Han SM, Cho YS, Choi MR, Park NG, Lee YS, Chang YC. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 2007; 40: 1069-1076